HRP20050053A2 - 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands - Google Patents

1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands

Info

Publication number: HRP20050053A2
Authority: HR; Croatia
Prior art keywords: cannabinoid; triazole; receptor ligands; carboxamide derivatives; carboxamide
Prior art date: 2002-09-19

Application number

HR20050053A

Other languages

English (en)

Inventor

Josephus

Cornelis

Andrew

Herman

Original Assignee

Solvay Pharmaceuticals B.V.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-19

Filing date

2003-07-19

Publication date

2005-04-30

2003-07-19 Application filed by Solvay Pharmaceuticals B.V. filed Critical Solvay Pharmaceuticals B.V.

2005-04-30 Publication of HRP20050053A2 publication Critical patent/HRP20050053A2/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Hematology (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Hospice & Palliative Care (AREA)
Urology & Nephrology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Child & Adolescent Psychology (AREA)
Addiction (AREA)
Vascular Medicine (AREA)
Otolaryngology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

HR20050053A 2002-09-19 2003-07-19 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands HRP20050053A2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02078966		2002-09-19
PCT/EP2003/050628 WO2004026301A1 (en)	2002-09-19	2003-09-17	1h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands

Publications (1)

Publication Number	Publication Date
HRP20050053A2 true HRP20050053A2 (en)	2005-04-30

Family

ID=31970417

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20050053A HRP20050053A2 (en)	2002-09-19	2003-07-19	1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands

Country Status (24)

Country	Link
US (1)	US7319110B2 (uk)
EP (1)	EP1542678B1 (uk)
JP (1)	JP2006501275A (uk)
KR (1)	KR100996828B1 (uk)
CN (1)	CN1319529C (uk)
AR (1)	AR041268A1 (uk)
AT (1)	ATE458479T1 (uk)
AU (1)	AU2003299024B2 (uk)
BR (1)	BR0312020A (uk)
CA (1)	CA2491394C (uk)
DE (1)	DE60331444D1 (uk)
DK (1)	DK1542678T3 (uk)
ES (1)	ES2341540T3 (uk)
HR (1)	HRP20050053A2 (uk)
IL (1)	IL165611A (uk)
MX (1)	MXPA05002862A (uk)
NO (1)	NO20051870L (uk)
PL (1)	PL375020A1 (uk)
PT (1)	PT1542678E (uk)
RU (1)	RU2325382C2 (uk)
SI (1)	SI1542678T1 (uk)
UA (1)	UA80298C2 (uk)
WO (1)	WO2004026301A1 (uk)
ZA (1)	ZA200500133B (uk)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6897240B2 (en) *	2002-05-08	2005-05-24	The Regents Of The University Of California	Thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use
EP1621537A4 (en) *	2003-04-21	2008-12-31	Daiichi Seiyaku Co	FIVE-GLASS HETEROCYCLIC DERIVATIVE
US7223780B2 (en) *	2003-05-19	2007-05-29	Sanofi-Aventis Deutschland Gmbh	Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
WO2005039550A2 (en) *	2003-10-24	2005-05-06	Solvay Pharmaceuticals Gmbh	Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds
BRPI0416639A (pt) *	2003-11-19	2007-01-16	Metabasis Therapeutics Inc	tiromiméticos contendo fósforo
US20060025448A1 (en)	2004-07-22	2006-02-02	Cadila Healthcare Limited	Hair growth stimulators
FR2874012B1 (fr) *	2004-08-09	2008-08-22	Sanofi Synthelabo	Derives de pyrrole, leur preparation et leur utlisation en therapeutique
ES2255834B1 (es) *	2004-09-14	2008-01-16	Laboratorios Del Dr. Esteve, S.A.	Nuevos derivados 1,2,4-triazol-3-carboxamida.
EP1802566B1 (en) *	2004-10-01	2008-11-26	F. Hoffmann-Roche AG	Hexafluoroisopropanol substituted ether derivatives
AU2005298692A1 (en)	2004-10-25	2006-05-04	Solvay Pharmaceuticals Gmbh	Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions
US7494985B2 (en) *	2004-11-03	2009-02-24	Xenoport, Inc.	Acyloxyalkyl carbamate prodrugs, methods of synthesis, and use
JP5137816B2 (ja) *	2005-04-29	2013-02-06	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	カンナビノイド受容体アンタゴニストとしてのベンゾトリアゾール誘導体
US7923465B2 (en)	2005-06-02	2011-04-12	Glenmark Pharmaceuticals S.A.	Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
JP2008545739A (ja)	2005-06-02	2008-12-18	グレンマーク・ファーマシューティカルズ・エスエー	新規なカンナビノイド受容体リガンド、それらを含む薬剤組成物、およびそれらの調製方法
US7632837B2 (en)	2005-06-17	2009-12-15	Bristol-Myers Squibb Company	Bicyclic heterocycles as cannabinoid-1 receptor modulators
TW200726765A (en) *	2005-06-17	2007-07-16	Bristol Myers Squibb Co	Triazolopyridine cannabinoid receptor 1 antagonists
CN101213182A (zh) *	2005-06-29	2008-07-02	阿斯利康(瑞典)有限公司	作为α7烟碱性受体调节剂的噻吩-2-甲酰胺
KR20080027908A (ko)	2005-06-30	2008-03-28	프로시디온 리미티드	Ｇｐｃｒ 효능제
FR2894579B1 (fr)	2005-12-12	2008-01-18	Sanofi Aventis Sa	Derives diaryltriazolmethylamine, leur preparation et leur application en therapeutique.
US7935715B2 (en)	2006-07-28	2011-05-03	Boehringer Ingelheim International Gmbh	Compounds which modulate the CB2 receptor
WO2008033572A1 (en) *	2006-09-15	2008-03-20	Xenoport, Inc.	Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
GB0700122D0 (en)	2007-01-04	2007-02-14	Prosidion Ltd	GPCR agonists
AR064735A1 (es)	2007-01-04	2009-04-22	Prosidion Ltd	Agonistas de gpcr y composicion farmaceutica en base al compuesto
JP2010514832A (ja)	2007-01-04	2010-05-06	プロシディオン・リミテッド	ピペリジンｇｐｃｒアゴニスト
CL2008000017A1 (es)	2007-01-04	2008-08-01	Prosidion Ltd	Compuestos derivados de heterociclos de nitrogeno y oxigeno, agonistas de gpcr; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la obesidad, diabetes, sindrome metabolico, hiperlipidemia, toleranci
HRP20110852T1 (hr)	2007-01-04	2011-12-31	Prosidion Limited	PIPERIDINSKI AGONISTI GPCR-a
CN101302200B (zh) *	2007-05-09	2011-04-20	上海医药工业研究院	制备n-哌啶子基-5-(4-氯苯基)-1-(2,4-二氯苯基)-4-甲基吡唑-3-甲酰胺的方法
GB0720390D0 (en)	2007-10-18	2007-11-28	Prosidion Ltd	G-Protein coupled receptor agonists
GB0720389D0 (en)	2007-10-18	2008-11-12	Prosidion Ltd	G-Protein Coupled Receptor Agonists
US8546563B2 (en)	2007-11-07	2013-10-01	Boehringer Ingelheim International Gmbh	Compounds which modulate the CB2 receptor
EP2265585B1 (en)	2008-02-21	2014-09-17	Boehringer Ingelheim International GmbH	Amine and ether compounds which modulate the cb2 receptor
EP2326629B1 (en)	2008-07-10	2013-10-02	Boehringer Ingelheim International GmbH	Sulfone compounds which modulate the cb2 receptor
WO2010036631A2 (en)	2008-09-25	2010-04-01	Boehringer Ingelheim International Gmbh	Compounds which selectively modulate the cb2 receptor
JP5583694B2 (ja)	2009-01-05	2014-09-03	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体を調節するピロリジン化合物
WO2010079241A1 (es)	2009-01-12	2010-07-15	Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion	Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas
US8889670B2 (en)	2009-02-18	2014-11-18	Boehringer Ingelheim International Gmbh	Heterocyclic compounds which modulate the CB2 receptor
US8299103B2 (en)	2009-06-15	2012-10-30	Boehringer Ingelheim International Gmbh	Compounds which selectively modulate the CB2 receptor
US8383615B2 (en)	2009-06-16	2013-02-26	Boehringer Ingelheim International Gmbh	Azetidine 2-carboxamide derivatives which modulate the CB2 receptor
WO2011037795A1 (en)	2009-09-22	2011-03-31	Boehringer Ingelheim International Gmbh	Compounds which selectively modulate the cb2 receptor
WO2011088015A1 (en)	2010-01-15	2011-07-21	Boehringer Ingelheim International Gmbh	Compounds which modulate the cb2 receptor
JP5746228B2 (ja)	2010-03-05	2015-07-08	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｂ２受容体を選択的に調節するテトラゾール化合物
US8846936B2 (en)	2010-07-22	2014-09-30	Boehringer Ingelheim International Gmbh	Sulfonyl compounds which modulate the CB2 receptor
CN102558157B (zh) *	2010-12-20	2014-04-30	中国科学院上海药物研究所	羟乙基三唑类化合物或氨乙基三唑类化合物及其制备方法和用途
CN102731418B (zh) *	2012-07-15	2015-03-11	浙江大学	1-取代-1h-1,2,4-三氮唑-甲酰胺衍生物及其制备和用途
CN104603129A (zh) *	2012-09-17	2015-05-06	霍夫曼-拉罗奇有限公司	三唑甲酰胺衍生物
EP2803668A1 (en)	2013-05-17	2014-11-19	Boehringer Ingelheim International Gmbh	Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
MA39999A (fr)	2014-06-06	2015-12-10	Res Triangle Inst	Agonistes du récepteur de l'apeline (apj) et leurs utilisations
JP6728198B2 (ja) *	2015-01-30	2020-07-22	ニューロクラインバイオサイエンシーズ，インコーポレイテッド	置換トリアゾールおよびそれに関する方法
RU2021133849A (ru)	2015-12-09	2022-03-21	Рисерч Трайэнгл Инститьют	Улучшенные агонисты апелинового рецептора (apj) и их использование
JP7104690B2 (ja) *	2016-10-12	2022-07-21	リサーチトライアングルインスティテュート	複素環式アペリン受容体（ａｐｊ）アゴニスト及びそれらの使用
WO2020103856A1 (en) *	2018-11-20	2020-05-28	Shanghaitech University	Mmpl3 inhibitors, compositions and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3316300A1 (de) *	1982-05-07	1983-11-24	Kureha Kagaku Kogyo K.K., Tokyo	Heribizide zusammensetzung mit einem gehalt an einem derivat des 1,2,4-triazols als wirkstoff
JPS58194866A (ja) *	1982-05-07	1983-11-12	Kureha Chem Ind Co Ltd	トリアゾ−ル誘導体及び該誘導体を含有する除草剤
DE3817192A1 (de) *	1988-05-20	1989-11-30	Hoechst Ag	1,2,4-triazolderivate enthaltende pflanzenschuetzende mittel sowie neue derivate des 1,2,4-triazols
FR2692575B1 (fr)	1992-06-23	1995-06-30	Sanofi Elf	Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
DE4225778A1 (de) *	1992-08-04	1994-02-17	Hoechst Ag	1,2,4-Triazolyl-3-carbonsäure-4-aminopiperidide, Verfahren zu ihrer Herstellung, sie enthaltende Mittel und ihre Verwendung als Schädlingsbekämpfungsmittel, insbesondere Fungizide
DE4425144A1 (de) *	1994-07-15	1996-01-18	Basf Ag	Triazolverbindungen und deren Verwendung
FR2741621B1 (fr) *	1995-11-23	1998-02-13	Sanofi Sa	Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2789079B3 (fr) *	1999-02-01	2001-03-02	Sanofi Synthelabo	Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
FR2796945B1 (fr) *	1999-07-30	2002-06-28	Sod Conseils Rech Applic	Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
CA2387892A1 (en)	1999-10-18	2001-04-26	University Of Connecticut	Pyrazole derivatives as cannabinoid receptor antagonists
FR2802206B1 (fr) *	1999-12-14	2005-04-22	Sod Conseils Rech Applic	Derives de 4-aminopiperidine et leur utilisation en tant que medicament
EP1254115A2 (en)	2000-02-11	2002-11-06	Bristol-Myers Squibb Company	Cannabinoid receptor modulators, their processes of preparation, and use of cannabinoid receptor modulators for treating respiratory and non-respiratory diseases

2003
- 2003-07-19 HR HR20050053A patent/HRP20050053A2/xx not_active Application Discontinuation
- 2003-09-16 US US10/662,477 patent/US7319110B2/en not_active Expired - Fee Related
- 2003-09-16 AR ARP030103347A patent/AR041268A1/es unknown
- 2003-09-17 AT AT03797318T patent/ATE458479T1/de active
- 2003-09-17 JP JP2004537155A patent/JP2006501275A/ja active Pending
- 2003-09-17 CA CA2491394A patent/CA2491394C/en not_active Expired - Fee Related
- 2003-09-17 ES ES03797318T patent/ES2341540T3/es not_active Expired - Lifetime
- 2003-09-17 WO PCT/EP2003/050628 patent/WO2004026301A1/en not_active Ceased
- 2003-09-17 EP EP03797318A patent/EP1542678B1/en not_active Expired - Lifetime
- 2003-09-17 PL PL03375020A patent/PL375020A1/xx not_active Application Discontinuation
- 2003-09-17 PT PT03797318T patent/PT1542678E/pt unknown
- 2003-09-17 MX MXPA05002862A patent/MXPA05002862A/es active IP Right Grant
- 2003-09-17 DK DK03797318.7T patent/DK1542678T3/da active
- 2003-09-17 CN CNB038173522A patent/CN1319529C/zh not_active Expired - Fee Related
- 2003-09-17 AU AU2003299024A patent/AU2003299024B2/en not_active Ceased
- 2003-09-17 SI SI200331803T patent/SI1542678T1/sl unknown
- 2003-09-17 KR KR1020057004584A patent/KR100996828B1/ko not_active Expired - Fee Related
- 2003-09-17 RU RU2005103244/04A patent/RU2325382C2/ru not_active IP Right Cessation
- 2003-09-17 BR BR0312020-1A patent/BR0312020A/pt not_active IP Right Cessation
- 2003-09-17 DE DE60331444T patent/DE60331444D1/de not_active Expired - Lifetime
- 2003-09-17 UA UAA200503704A patent/UA80298C2/uk unknown
2004
- 2004-12-07 IL IL165611A patent/IL165611A/en not_active IP Right Cessation
2005
- 2005-01-06 ZA ZA200500133A patent/ZA200500133B/en unknown
- 2005-04-18 NO NO20051870A patent/NO20051870L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO2004026301A1 (en)	2004-04-01
US7319110B2 (en)	2008-01-15
UA80298C2 (en)	2007-09-10
US20040106614A1 (en)	2004-06-03
DK1542678T3 (da)	2010-06-07
DE60331444D1 (de)	2010-04-08
EP1542678B1 (en)	2010-02-24
CN1671377A (zh)	2005-09-21
IL165611A0 (en)	2006-01-15
ATE458479T1 (de)	2010-03-15
RU2325382C2 (ru)	2008-05-27
RU2005103244A (ru)	2005-06-27
EP1542678A1 (en)	2005-06-22
IL165611A (en)	2010-04-15
PT1542678E (pt)	2010-05-25
CN1319529C (zh)	2007-06-06
MXPA05002862A (es)	2005-05-27
BR0312020A (pt)	2005-03-22
CA2491394C (en)	2010-06-15
KR20050057399A (ko)	2005-06-16
SI1542678T1 (sl)	2010-07-30
CA2491394A1 (en)	2004-04-01
AU2003299024A1 (en)	2004-04-08
AR041268A1 (es)	2005-05-11
KR100996828B1 (ko)	2010-11-29
ZA200500133B (en)	2005-11-01
NO20051870L (no)	2005-06-03
HK1078796A1 (en)	2006-03-24
PL375020A1 (en)	2005-11-14
AU2003299024B2 (en)	2008-03-06
ES2341540T3 (es)	2010-06-22
JP2006501275A (ja)	2006-01-12

Publication	Publication Date	Title
HRP20050053A2 (en)	2005-04-30	1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
AP2005003368A0 (en)	2005-09-30	PyrazoloÄ1,5-AÜÄ1,3,5Ütriazine derivatives as cannabinoid receptor ligands.
IL160181A0 (en)	2004-07-25	N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands
EG23424A (en)	2005-07-12	Fungicidal azo-carboxamide derivatives.
PL377295A1 (pl)	2006-01-23	Pochodne 4,5-diarylotiazolu jako ligandy CB-1
SI1699795T1 (sl)	2007-10-31	Substituirani 8-piri(mi)dinil-dihidrospiro-(cikloalkilamin)pirimido(1,2a) pirimidin-6-onski derivati
PL368672A1 (en)	2005-04-04	Novel 1,2,4-triazole compound
SI1555267T1 (sl)	2013-05-31	2,3-DIHIDRO-6-NITROIMIDAZO(2,1-b)OKSAZOLI
ZA200606974B (en)	2008-04-30	Substituted 1,2,3,4-tetrahydrolsoquinoline derivatives
AP2005003198A0 (en)	2005-03-31	Spiroindolinepiperidine derivatives.
ZA200500170B (en)	2006-02-22	Indole-3-sulphur derivatives.
ZA200409339B (en)	2006-02-22	Novel benzimidazole derivatives.
SI2308855T1 (sl)	2013-01-31	2,4-diaminopirimidinski derivati
PL376311A1 (en)	2005-12-27	Purine compounds and uses thereof as cannabinoid receptor ligands
AU2003257172A1 (en)	2004-02-25	Cannabinoid receptor ligands
IL164922A0 (en)	2005-12-18	(Imidazol-1-yl-methyl)-pyridazine as nmda receptorblocker
PL373953A1 (en)	2005-09-19	7-amino-benzothiazole derivatives as adenosine receptor ligands
PL369470A1 (en)	2005-04-18	Benzothiazole derivatives as adenosine receptor ligands
ZA200506744B (en)	2006-06-28	PyrazoloÄ1,5-AÜpyrimidine derivatives
AU2003247706A1 (en)	2004-02-16	6, 11-4-carbon bridged erythromycin derivatives
PL373695A1 (en)	2005-09-05	Melanocortin receptor ligands
IL162444A0 (en)	2005-11-20	Triazolo-quinolin derivatives useful as adenosine receptor ligands
AU3167402A (en)	2002-06-24	Aminotriazolopyridiine derivatives as adenosine receptor ligands
AU2003294449A1 (en)	2004-06-18	Cannabinoid receptor ligands
ZA200408029B (en)	2005-10-06	Novel 1,3,5-triazine derivatives as ligands for human adenosine-A3 receptors.

Legal Events

Date	Code	Title	Description
2005-04-28	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2005-04-30	A1OB	Publication of a patent application
2010-09-06	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20100906 Year of fee payment: 8
2012-02-07	OBST	Application withdrawn
2025-09-12	A8IS	Corrected front page of an hr-a document